-
When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney diseaseE O'Meara, S Verma. -
Nitrosative stress drives heart failure with preserved ejection fractionSchiattarella GG, Altamirano F, Hill JA et al.
-
Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart FailureCK Nagaraju, EL Robinson, KR Sipido et al.
-
The year in cardiovascular medicine 2020: heart failure and cardiomyopathiesH Bueno, B Moura, P Lancellotti et al.
-
How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)Pieske B Tschöpe C, de Boer RA et al.
-
Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesSD Wiviott，I Raz，DECLARE–TIMI 58 Investigators.
-
H2FPEF Score for Predicting Future Heart Failure in Stable Outpatients With Cardiovascular Risk FactorsSatoru Suzuki , K Kaikita, E Yamamoto et al.
-
Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV TrialF Cosentino , CP Cannon , DZI Cherney et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
